Scientific Program

Print
THURSDAY , 22 OCTOBER 2015
 07:30-20:00
Registration
18:45-20:00
Welcome Reception & Exhibition

FRIDAY , 23 OCTOBER 2015
 
HALL A
08:30-08:35 Opeining Remarks: A. Nagler, Israel and N. Kröger, Germany
08:35-10:15
Plenary Session 1: Alternative Donors and Cell Therapy
 
In case of no matched donor cord blood vs. haplo vs. MUD
08:35-08:40
Moderator: N. Kröger, Germany
08:40-08:55
Pro cord blood: E. Gluckman, France
08:55-09:10
Pro haplo: A. Bacigalupo, Italy
09:10-09:25 Pro MUD: A. Nagler, Israel
09:25-09:35
Discussion
 
Is CAR the best T-cell based therapy?
09:35-09:40 Moderator: A. Nagler. Israel
09:40-09:55
Yes: S. Grupp, USA
09:55-10:10
No: C. Bonini, Italy
10:10-10:20
Discussion
10:20-10:45
Coffee Break
 
HALL A
 
HALL B
10:45-12:15
Session 2: Acute Myeloid Leukaemia
10:45-12:15
Session 3: CMV Infection and Stem Cell Mobilisation
 
Does size of FLT3 clone influence transplant indication?
 
Drug vs. cell therapy for CMV
10:45-10:50
Moderator: J. Cornelissen, The Netherlands
10:45-10:50
Moderator: J.M. Rowe, Israel
10:50-11:05
Yes: G. Ehninger, Germany
10:50-11:05
Pro drug: P. Ljungman, Sweden
11:05-11:20
No: C. Craddock, UK
11:05-11:20
Pro cell therapy: K. Peggs, UK
11:20-11:30
Discussion
11:20-11:30
Discussion
 
Is there any role of second allograft for relapsed AML?
 
High CD34+ cell collection target in autologous transplantation: just nice to have?
11:30-11:35
Moderator: M. Mohty, France
11:30-11:35
Moderator: K. Hübel, Germany
11:35-11:50
Yes: C. Schmid, Germany
11:35-11:50
Yes: A. Curti, Italy
11:50-12:05
No: J. Cornelissen, The Netherlands
11:50-12:05
No: N. Worel, Austria
12:05-12:15
Discussion
12:05-12:15
Discussion
12:15-13:00
Lunch
13:00-14:00
14:00-15:30
Session 4: ALL
14:00-15:30
Session 5: Post Transplant Immunotherapy (I)
 
Is consolidation required before transplant?
 
Should minimal residual disease be treated in AML?
14:00-14:05
Moderator: R. Arnold, Germany
14:00-14:05
Moderator: C. Schmid, Germany
14:05-14:20
Yes: D. Hoelzer, Germany
14:05-14:20
Yes: C. Craddock, UK
14:20-14:35
No: J. M. Rowe, Israel
14:20-14:35
No: R. Gale, UK
14:35-14:45
Discussion
14:35-14:45
Discussion
 
Is TBI still the standard conditioning in ALL?
 
Best approach for residual disease after transplant for ALL
14:45-14:50
Moderator: J. M. Rowe, Israel
14:45-14:50
Moderator: D. Hoelzer, Germany
14:50-15:05
Yes: A. Shimoni, Israel
14:50-15:05
Cell based: H. J. Kolb, Germany
15:05-15:20
No: D. Marks, UK
15:05-15:20
Antibody: M. Mohty, France
15:20-15:30
Discussion
15:20-15:30
Discussion
15:30-16:00
Coffee Break
16:00-17:30
Session 6: CLL and MCL
16:00-17:30
Session 7: Post Transplant Immunotherapy (II)
 
Is there still any indication for allogeneic SCT in CLL?
 
Best post transplant immunotherapy for Myeloma and lymphoma?
16:00-16:05
Moderator: R. Arnold, Germany
16:00-16:05
Moderator: A. Nagler, Israel
16:05-16:20
Yes: I. Khouri, USA
16:05-16:20
Vacination: D. Avigan, USA
16:20-16:35
No: M. Herling, Germany
16:20-16:35
Tumorspecific T-Cells : D. Atanackovic, USA
16:35-16:45
Discussion
16:35-16:45
Discussion
 
Is autologous SCT still the appropriate upfront treatment for MCL?
 
After relapse to autograft in myeloma should allograft or another autograft be done?
16:45-16:50
Moderator: I. Khouri, USA
16:45-16:50
Moderator: D. Avigan, USA
16:30-17:05
Yes: S. Robinson, UK
16:30-17:05
Allo: B. Bruno, Italy
17:05-17:20
No: C. Gisselbrecht, France
17:05-17:20
Auto: L. Garderet, France
17:20-17:30
Discussion
17:20-17:30
Discussion

SATURDAY , 24 OCTOBER 2015
 
HALL A
 
HALL B
08:30-10:00
Plenary Session 8: MDS
 
Session 9: Acute GvHD
 
RIC is the preferred conditioning regimen for all MDS patients.
08:30-10:00
Did we make progression in treatment of a steroid refractory GvHD?
08:30-08:50
Moderator: C. Craddock, UK
08:30-08:35
Moderator: J. Levine, USA
08:35-08:50
Yes: N. Kröger, Germany
08:35-08:55
Yes by antibodies: A. Olivieri, Italy
08:50-09:05
No: I. Yakoub-Agha, France
08:55-09:10
Yes by pharmacological agents:
E. Holler, Germany
09:05-09:15
Discussion
09:10-09:25
Yes by cell therapy: M. Bornhäuser, Germany
 
Is it time to select low and intermediate I MDS patient for transplantation according to molecular genetic?
09:25-09:40
No: W. Arcese, Italy
 
09:40-10:00
Discussion
09:15-09:20
Moderator: N. Kröger, Germany
 
 
09:20-09:35
Yes: M. G. Della Porta, Italy
 
 
09:35-09:50
No: V. Santini, Italy
 
 
09:50-10:00
Discussion
 
 
10:00-10:30
Coffee Break
 
HALL A
 
HALL B
10.30-12:00
Session 10: Myeloma
10.30-12:00
Session 11: Chronic GvHD
 
Is upfront autologous or allogeneic curative for Myeloma
 
Did we make any progression in treatment of chronic GvHD?
10:30-10:35
Moderator: N. Kröger, Germany
10:30-10:35
Moderator: A. Rambaldi, Italy
10:35-10:50
Pro auto: F. vann Rhee, USA
10:35-10:50
Yes by photopheresis: H. Greinix, Austria
10:50-11:05
Pro allo: G. Gahrton, Sweden
10:50-11:05
Yes by pharmacological agents: F. Ayuk, Germany
11:05-11:15
Discussion
11:05-11:20
Yes by antiobodies: D. Wolff, Germany
 
Is maintenance after autologous SCT 2015 the standard care of treatment?
11:20-11:35
No: P. Martin, USA
11:15-11:20
Moderator: A. Nagler, Israel
11:35-12:00
Discussion
11:20-11:35
Yes: N. Kröger, Germany
 
 
11:35-11:50
No: M. Mohty, France
 
 
11:50-12:00
Discussion
 
 
12:00-12:30
Lunch
12:30-13:30
13:30-15:00
Session 12: Lymphoma
13:30-15:00
Session 13: Acute and Chronic GvHD
 
Is there any role for allogeneic SCT in Hodgkin Lymphoma?
 
Did we make any progress in prevention acute and chronic GvHD?
13:30-13:35
Moderator: A. Sureda, Spain
13:30-13:35
Moderator: E. Holler, Germany
13:35-13:50
Yes: S. Mackinnon, UK
13:35-13:50
Yes by T-cell antibodies: J. Finke, Germany
13:50-14:05
No: A. Avigdor, Israel
13:50-14:05
Yes by T-Cell depetion: M. Pasquini, USA
14:05-14:15
Discussion
14:05-14:20
Yes by pharmacological agents: J. A. Perez-Simon, Spain
 
The best treatment option for early relapse in diffuse large B-cell Lymphoma in…
14:20-14:35
Yes by predicting the occurrence: J. Levine, USA
 
14:35-15:00
Discussion
14:15-14:20
Moderator: S. Robinson, UK
 
 
14:20-14:35
autologous SCT: C. Gisselbrecht, France
 
 
14:35-14:50
allogeneic SCT: A. Sureda, Spain
 
 
14:50-15:00
Discussion
 
 
15:00-15:30
Coffee Break
15:30-17:00
Session 14: Toxicity and CML
15:30-17:00
Session 15: Aplastic Anemia
 
Is VOD still a problem in the era of RIC?
 
Can unrelated donor be used a first line treatment for Aplastic Anemia?
15:30-15:35
Moderator: E. Olavarria, UK
15:30-15:35
Moderator: A. Bacigalupo, Italy
15:35-15:50
Yes: M. Mohty, France
15:35-15:50
Yes: C. Dufour, Italy
15:50-16:05
No: M. Bornhäuser, Germany
15:50-16:05
No: J. Passweg, Switzerland
16:05-16:15
Discussion
16:05-16:15
Discussion
 
Is there any role of allo SCT for CML in chronic phase?
 
Is haplo-identical SCT justified in patients with AA?
16:15-16:20
Moderator: R. Hehlmann, Germany
16:15-16:20 
Moderator: C. Dufour, Italy
16:20-16:35
Yes: E. Olavarria, UK
16:20-16:35
Yes: A. Bacigalupo, Italy
16:35-16:50
No: G. Saglio, Italy
16:35-16:50
No: R. Storb, USA
16:50-17:00
Discussion
16:50-17:00
Discussion
15:30-18:30 Workshop – Limited Availability – In parallel to the scientific program
17:00-17:30 Poster viewing and Poster Abstract Award Ceremony
Presented by: Abstract Review Committee

SUNDAY , 25 OCTOBER 2015
 
HALL A
08:30-10:00
Session 16: Cellular Therpay
 
The trump card in cellular therapy?
08:30-08:35
Moderator: L. Uharek, Germany
08:35-08:50
T-Cell: J.H.F. Falkenburg, The Netherlands
08:50-09:10
NK Cell: J. Miller, USA
09:05-09:15
Discussion
 
Is the hype of T-reg cell justified?
09:15-09:20
Moderator: J.H.F. Falkenburg, The Netherlands
09:20-09:35
Yes: M. Edinger, Germany
09:35-09:50
No: A. Rambaldi, Italy
09:50-10:00
Discussion
10:00-10:30
Coffee Break
10.30-12:00
Session 17: Haplo-Identical Transplantation
 
Haplo: T-cell repleted or T-cell depleted. How to perform best haplo?
10:30-10:35
Moderator: R. Storb, USA
10:35-10:50
T-cell depletion: R. Handgretinger, Germany
 
T-cell repleted:
10:50-11:05
a) post cyclo: E. Fuchs, USA
11:05-11:20
b) G-CSF stimulated BM: X. J. Huang, China
11:20-11:35
c) Focus on T-regs: F. Ciceri, Italy
11:35-11:50
Discussion
11:50-12:00
Closing Ceremony